appears presentation was held on 15th in the US and shares remained flat with no change in price. I guess its either presented after market or its same news. I like their thinking about using drug in first line therapy based on earlier trials as a last resort drug. The lack of share reaction makes me wonder if another company is more advanced with competing drugs?, anyone shine any info on this
appears presentation was held on 15th in the US and shares...
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)